Find a Clinical Trial | American Lung Association

AERIFY-2

Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD

ARISE and ENCORE Studies for Patients with MAC Lung Disease

To evaluate a potential treatment for MAC lung infection and its impact on symptoms including respiratory discomfort and fatigue.

ASPEN

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis

BATURA

The purpose of the study, called AV007/BATURA, is to see if the study drug PT027 (budesonide/albuterol metered dose inhaler [MDI] 80/90 µg) compared with PT007 (albuterol MDI 90 µg) is safe and effective in treating asthma.

CALM-2

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

CASCADE-LUNG

Purpose or description of this study: We are recruiting approximately 15,000 individuals for a large-scale study to help determine the ability of our simple, blood-based screening technology to detect lung cancer accurately and reliably.

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis (RheSolve)

This is a prospective, randomized, parallel group, double-blind, sham-controlled, multicenter clinical trial following patients to 2 years. The objective is to assess the safety and effectiveness of Bronchial Rheoplasty for the treatment of the symptoms of chronic bronchitis in adult COPD patients with moderate to severe chronic bronchitis. A total of 270 patients will be randomized at up to 40 study centers in the United States, Canada, and Europe.

EFC15858

Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors

ELEVATE

The ELEVATE study is evaluating the safety and efficacy of the investigational drug LYT-100 (deupirfenidone) in people living with IPF. LYT-100 has been modified in a way that slows down metabolism of the drug compared to pirfenidone and has demonstrated improved tolerability compared to pirfenidone in previous studies.

Exablate

The primary objective is to evaluate the safety and efficacy of blood brain barrier disruption using the Exablate Type 2 system in adult subjects with brain metastases of NSCLC origin that are either undergoing or have planned standard of care pembrolizumab monotherapy as compared to subjects that are undergoing standard of care pembrolizumab without Exablate blood brain barrier disruption.

Next